Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD

Απλή σελίδα τεκμηρίου
dc.contributor.authorSiamopoulos, K. C.en
dc.contributor.authorGouva, C.en
dc.contributor.authorKatopodis, K. P.en
dc.contributor.authorTzallas, C.en
dc.contributor.authorNikolopoulos, P.en
dc.contributor.authorPapavasiliou, E. C.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T16:41:13Z
dc.date.available2015-11-24T16:41:13Z
dc.identifier.issn0272-6386-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/8384
dc.rightsDefault Licence-
dc.subjectrenal anemiaen
dc.subjecterythropoietin (epo)en
dc.subjectlipidsen
dc.subjectchronic kidney disease (ckd)en
dc.subjectrecombinant-human-erythropoietinen
dc.subjectester transfer proteinen
dc.subjectpaf-acetylhydrolase activityen
dc.subjectactivating factor-acetylhydrolaseen
dc.subjectcoronary-heart-diseaseen
dc.subjectchronic kidney-diseaseen
dc.subjecthemodialysis-patientsen
dc.subjectrenal-failureen
dc.subjectlipid profileen
dc.subjectrisk-factoren
dc.titleLong-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKDen
heal.abstractBackground. Among lipid abnormalities observed in patients with chronic kidney disease (CKD) is a significant decrease in serum high-density lipoprotein cholesterol (HDL-C) levels. In a previously published randomized control trial, we showed that early erythropoietin (EPO) administration in a predialysis population slowed the progression of CKD. In the present nested substudy, we examine whether EPO has an influence on serum HDL-C levels in comparison to other lipid parameters in this population. Methods: Eighty-eight patients with CKD stages 3 and 4 were enrolled in the study. Forty-five patients (group 1) were treated with EPO (50 U/kg/wk), targeting to increase hemoglobin levels to 13 g/dL or greater ( >= 130 g/L). The other patients (group 2) remained without treatment until hemoglobin levels decreased to less than 9 g/dL (<90 g/L). The duration of the study was 12 months. Results: At the end of the study, we observed a statistically significant decrease in serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides in both groups. However, serum HDL-C levels significantly increased in only group 1 (from 42.5 +/- 10.4 to 55.9 +/- 8.1 mg/dL [1.10 +/- 0.27 to 1.45 +/- 0.21 mmol/L]; P < 0.001), whereas they were unchanged in group 2. In addition, a significant decrease in atherogenic LDL-C/HDL-C ratio was observed in only group 1. Importantly, the increase in serum HDL-C levels correlated positively with the increase in hemoglobin values in EPO-treated patients. Conclusion: Our results show that EPO treatment of predialysis patients with CKD significantly increases serum HDL-C levels, which may represent an important antiatherogenic effect of this hormone.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDOI 10.1053/j.ajkd.2006.04.071-
heal.identifier.secondary<Go to ISI>://000239629700008-
heal.journalNameAmerican Journal of Kidney Diseasesen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2006-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ